This article discusses development of polymeric nanoparticles intended to obtain optimal features for loading therapeutic antibodies and be formulated into dry powders for inhalable lung cancer treatment. This may reduce serious side effects and toxicity and support therapeutic adherence, effectiveness and safety. The article also discusses dry powder formulation with respect to particle deposition profile and the spray-drying process.
Pulmonary delivery of dry powders can enable targeted cancer therapy to reach the lung. In turn, therapeutic antibodies used as lung anti-cancer therapy could be delivered by inhalation. Antibody nanoencapsulation may play a key role in antibody stability and maintenance of bioactivity. An additional process of microencapsulation through spray drying can provide nanoparticles with characteristics to support lung delivery. Further studies are necessary to evaluate antibody structure and bioactivity preservation after drying, as well as interactions with the microparticle matrix.